Oral Probiotics vs Placebo Pakistani Moderate Acne Study
ClinicalTrials.gov Studies
Summary
ClinicalTrials.gov registered a randomized controlled trial (NCT07539129) evaluating oral probiotics versus placebo in 64 Pakistani patients with moderate Acne Vulgaris over 12 weeks. The primary endpoint is reduction in total acne lesion count; secondary endpoint is change in serum Interleukin-6 levels. The study will use GAGS scoring and standardized photography for clinical assessment.
What changed
This document registers a clinical trial (NCT07539129) investigating oral probiotics as an alternative to antibiotics for moderate acne, reflecting interest in the gut-skin axis. The trial will enroll 64 patients randomized to probiotic or placebo groups for 12 weeks of treatment.
For compliance purposes, this study registration does not create immediate obligations. However, clinical research sponsors, contract research organizations, and investigators conducting dermatology or microbiome research should note this trial as a registered investigation that may inform future regulatory submissions or publication of results, which could influence review of probiotic-based or antibiotic-sparing dermatology therapies.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation
N/A NCT07539129 Kind: NA Apr 20, 2026
Abstract
This randomized controlled trial evaluates the efficacy of oral probiotics compared to placebo in Pakistani patients with moderate Acne Vulgaris. Acne is a multifactorial inflammatory disorder influenced by microbial colonization, seborrhea, and immune dysregulation. Rising antibiotic resistance necessitates alternative therapeutic approaches. Emerging evidence highlights the gut-skin axis, suggesting probiotics may reduce systemic inflammation and acne severity. A total of 64 patients will be randomized into probiotic and placebo groups and treated for 12 weeks. The primary outcome is reduction in total acne lesion count, while the secondary outcome is change in serum Interleukin-6 levels. Clinical assessment includes lesion counts, GAGS scoring, and standardized photography. IL-6 levels will be measured using ELISA at baseline and study completion. Data will be analyzed using SPSS with appropriate statistical tests, considering p ≤ 0.05 as significant. This study aims to provide evidence for probiotics as a safe, effective, and antibiotic-sparing option in acne management, particularly in South Asian populations.
Conditions: Acne Vulgaris
Interventions: Probiotics, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.